ConductScience.org, home

Paper32989604

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.

Huang S and 3 others. J Cancer Res Clin Oncol, 2020. Cited by 92 papers, by iCite.

Cite this record

ConductScience Library. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Papers, record 32989604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32989604

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
PubMed
Journal
J Cancer Res Clin Oncol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
92
iCite
Relative citation ratio, by iCite
3.92
iCite
Revised in PubMed
2024-08-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang SShuyu
2van Duijnhoven SMJSander M J
3Sijts AJAMAlice J A M
4van Elsas AAndreahttps://orcid.org/0000-0002-2966-114X

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, BispecificMajor topic
Antigens, NeoplasmMajor topic
NeoplasmsMajor topic
Humans

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
765394H2020 Marie Skłodowska-Curie ActionsPubMed

Source PubMed

Download CSV of grants

References82

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19317136Flexibility of human IgG subclasses.J Immunol1997https://conductscience.org/library/papers/9317136PubMed
227037412RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.Mol Cancer Ther2016https://conductscience.org/library/papers/27037412PubMed
326374073FDA Approval: Blinatumomab.Clin Cancer Res2015https://conductscience.org/library/papers/26374073PubMed
428405494Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Oncoimmunology2017https://conductscience.org/library/papers/28405494PubMed
529155426CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med2018https://conductscience.org/library/papers/29155426PubMed
6314668Monoclonal antibodies defining distinctive human T cell surface antigens.Science1979https://conductscience.org/library/papers/314668PubMed
719692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
829743205Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.Mol Cancer Ther2018https://conductscience.org/library/papers/29743205PubMed
912621007Pretargeted radioimmunotherapy of cancer: progress step by step.J Nucl Med2003https://conductscience.org/library/papers/12621007PubMed
1032414908Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Cancer Discov2020https://conductscience.org/library/papers/32414908PubMed
1131685488MCLA-128 Fights NRG1 Fusion-Positive Cancers.Cancer Discov2019https://conductscience.org/library/papers/31685488PubMed
1232006223Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.Clin Pharmacokinet2020https://conductscience.org/library/papers/32006223PubMed
1313729245Properties of the major component of a peptic digest of rabbit antibody.Science1960https://conductscience.org/library/papers/13729245PubMed
1411597399EGFR and cancer prognosis.Eur J Cancer2001https://conductscience.org/library/papers/11597399PubMed
1531442474Mechanisms of acquired tumor drug resistance.Biochim Biophys Acta Rev Cancer2019https://conductscience.org/library/papers/31442474PubMed
1629192287Next generation antibody drugs: pursuit of the 'high-hanging fruit'.Nat Rev Drug Discov2018https://conductscience.org/library/papers/29192287PubMed
179231898Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.J Mol Biol1997https://conductscience.org/library/papers/9231898PubMed
1831772172On-target restoration of a split T cell-engaging antibody for precision immunotherapy.Nat Commun2019https://conductscience.org/library/papers/31772172PubMed
1927742718Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.EMBO Mol Med2016https://conductscience.org/library/papers/27742718PubMed
2021613623Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.Sci Transl Med2011https://conductscience.org/library/papers/21613623PubMed

See all 82 referencesDownload CSV of references

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.

PMIDTitleJournalYearIn PapersSource
42818194Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma.bioRxiv2026https://conductscience.org/library/papers/42818194PubMed
42200831Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.Antibodies (Basel)2026https://conductscience.org/library/papers/42200831PubMed
42115599The evolving global landscape of first-in-class oncology drug innovation.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42115599PubMed
41898489ASGR2 and CLEC12A as Prognostically Relevant C-Type Lectin Hubs in Glioblastoma.Int J Mol Sci2026https://conductscience.org/library/papers/41898489PubMed
41832248Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discov Oncol2026https://conductscience.org/library/papers/41832248PubMed
41709436Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.Microbiologyopen2026https://conductscience.org/library/papers/41709436PubMed
41601637Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.Front Immunol2025https://conductscience.org/library/papers/41601637PubMed
41586193Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.Iran J Basic Med Sci2025https://conductscience.org/library/papers/41586193PubMed
41348261Advancing breast cancer treatment through dual targeting CAR T cell therapy.Discov Oncol2025https://conductscience.org/library/papers/41348261PubMed
41211166Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/41211166PubMed
41154706Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma.Biomolecules2025https://conductscience.org/library/papers/41154706PubMed
41016975Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.J Egypt Natl Canc Inst2025https://conductscience.org/library/papers/41016975PubMed
40909165Advances of bispecific antibodies using/application in dermatology: a review.Front Allergy2025https://conductscience.org/library/papers/40909165PubMed
40565299Bispecific Antibodies in Solid Tumors: Advances and Challenges.Int J Mol Sci2025https://conductscience.org/library/papers/40565299PubMed
40508128From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.Int J Mol Sci2025https://conductscience.org/library/papers/40508128PubMed
40427532Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy.Biomolecules2025https://conductscience.org/library/papers/40427532PubMed
40352940Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward?Front Immunol2025https://conductscience.org/library/papers/40352940PubMed
40155973Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.Biomark Res2025https://conductscience.org/library/papers/40155973PubMed
40106158Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer.BioDrugs2025https://conductscience.org/library/papers/40106158PubMed
39990653Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.Int J Biol Sci2025https://conductscience.org/library/papers/39990653PubMed

See all 62 cited byDownload CSV of cited by

Genes27

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD22933PubTator's text mininghttps://conductscience.org/library/genes/933NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD47961PubTator's text mininghttps://conductscience.org/library/genes/961NCBI Gene
CD63967PubTator's text mininghttps://conductscience.org/library/genes/967NCBI Gene
CD79A973PubTator's text mininghttps://conductscience.org/library/genes/973NCBI Gene
CEACAM51048PubTator's text mininghttps://conductscience.org/library/genes/1048NCBI Gene
CEP7080321PubTator's text mininghttps://conductscience.org/library/genes/80321NCBI Gene
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EPCAM4072PubTator's text mininghttps://conductscience.org/library/genes/4072NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
FAP2191PubTator's text mininghttps://conductscience.org/library/genes/2191NCBI Gene
FCGR3A2214PubTator's text mininghttps://conductscience.org/library/genes/2214NCBI Gene
FCGRT2217PubTator's text mininghttps://conductscience.org/library/genes/2217NCBI Gene
HGF3082PubTator's text mininghttps://conductscience.org/library/genes/3082NCBI Gene
IGHE3497PubTator's text mininghttps://conductscience.org/library/genes/3497NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene

See all 27 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32989604

GET https://conductscience.org/api/papers/v1/32989604/references?page=2